MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-03-2023
Paratek Pharmaceuticals Total Assets 2011-2026 | PRTK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 184 M | 177 M | 251 M | 300 M | 164 M | 136 M | 146 M | 110 M | 73.7 M | 98.1 M | 69.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 300 M | 69.2 M | 157 M |
Quarterly Total Assets Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 146 M | 151 M | 173 M | 157 M | - | 170 M | 184 M | 182 M | 180 M | 159 M | 177 M | 177 M | 177 M | 177 M | 251 M | 251 M | 251 M | 251 M | 300 M | 300 M | 300 M | 300 M | 164 M | 164 M | 164 M | 164 M | 136 M | 136 M | 136 M | 136 M | 146 M | 146 M | 146 M | 146 M | 110 M | 110 M | 110 M | 110 M | 1.28 M | 73.7 M | 73.7 M | 73.7 M | 98.1 M | 98.1 M | 98.1 M | 98.1 M | 69.2 M | 69.2 M | 69.2 M | 69.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 300 M | 1.28 M | 154 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
11.2 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 19.14 | 0.74 % | $ 895 M |  USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 14.74 | -0.2 % | $ 216 M | USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.63 | 3.5 % | $ 434 M |  Britain |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
BioNTech SE
BNTX
|
22 B | $ 94.9 | 0.82 % | $ 22.9 B | Germany |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
466 M | $ 3.13 | -0.48 % | $ 651 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Exelixis
EXEL
|
2.84 B | $ 49.35 | 2.47 % | $ 13.4 B | USA |
 |
Fortress Biotech
FBIO
|
186 M | $ 2.36 | -1.26 % | $ 65.8 M | USA |
 |
Forte Biosciences
FBRX
|
82.8 M | $ 24.9 | 3.65 % | $ 322 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 203.32 | 0.97 % | $ 360 B | USA |
 |
Gilead Sciences
GILD
|
59 B | $ 133.2 | 1.42 % | $ 166 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.82 | -2.76 % | $ 263 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
2.33 B | $ 0.77 | 0.16 % | $ 35.2 M | Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.41 | 0.04 % | $ 3.71 B | USA |
 |
Genprex
GNPX
|
10.2 M | $ 0.85 | -1.99 % | $ 793 K | USA |
 |
Genmab A/S
GMAB
|
45.8 B | $ 26.36 | -0.26 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.46 | -1.98 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.05 | -0.62 % | $ 5.47 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 21.09 | -0.4 % | $ 2.68 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |